Summary of opinion: Mekinist, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 11:00
Summary of opinion: Mekinist, 26/03/2026 Positive
Human medicines European public assessment report (EPAR): Blarcamesine Anavex, blarcamesine, Status: Application withdrawn
Submitted by Anonymous (not verified) on 27 March 2026 - 11:00
Human medicines European public assessment report (EPAR): Blarcamesine Anavex, blarcamesine, Status: Application withdrawn
Summary of opinion: Sarclisa, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 11:00
Summary of opinion: Sarclisa, 26/03/2026 Positive
Summary of opinion: Imcivree, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 11:00
Summary of opinion: Imcivree, 26/03/2026 Positive
Summary of opinion: Mekinist, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 10:39
Summary of opinion: Mekinist, 26/03/2026 Positive
Melatonin product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 27 March 2026 - 7:22
Melatonin product-specific bioequivalence guidance
Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 28, Status: Authorised
Submitted by Anonymous (not verified) on 26 March 2026 - 16:26
Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 28, Status: Authorised
Human medicines European public assessment report (EPAR): Lenvima, lenvatinib, Date of authorisation: 28/05/2015, Revision: 28, Status: Authorised
Submitted by Anonymous (not verified) on 26 March 2026 - 16:25
Human medicines European public assessment report (EPAR): Lenvima, lenvatinib, Date of authorisation: 28/05/2015, Revision: 28, Status: Authorised
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 3, Status: Authorised
Submitted by Anonymous (not verified) on 26 March 2026 - 13:28
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 3, Status: Authorised
Orphan designation: puliretgene parvec Treatment of inherited retinal dystrophy due to dysfunction in the CYP4V2-gene, 12/09/2025 Positive
Submitted by Anonymous (not verified) on 26 March 2026 - 13:22
Orphan designation: puliretgene parvec Treatment of inherited retinal dystrophy due to dysfunction in the CYP4V2-gene, 12/09/2025 Positive